<p>A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany</p>

• DOI: 10.2147/ijwh.s193048
• Publication Date: 2019-05-12T23:11:23Z
• Authors: Weiguang Xue; Adam Lloyd; Edel Falla; Claudia Roeder; Rudiger Papsch; Klaus Bühler
• Keywords: Biosimilar; Alpha (finance)

Background and objectives: Demand for assisted reproduction technology (ART) in Germany is high, with 100,844 treatment cycles during 2016. Many ART procedures involve ovarian stimulation follicle stimulating hormone (FSH). Recently, biosimilar FSH products have become available. The objective of this study was to evaluate the cost-effectiveness recombinant Gonal-f® (Originator) comparison follitropin alfa, Bemfola® (Biosimilar 1) Ovaleap® 2), from a German payer perspective terms cost per live birth. Methods: A decision tree model developed, based on one cycle reproduction, compare original product biosimilars. Clinical inputs, including birth rates adverse event were obtained published randomized trials. Cost inputs publicly available sources. structure methodology previous publications validated by clinical expert. Results: Results indicated that rate higher Originator compared Biosimilar 1 (40.7% vs 32.1% respectively), 2 (32.2% 26.8%). average women treated estimated be lower than those who biosimilars: (€10,510 €12,192), (€12,590 €13,606). analysis also found associated an incremental €4,168 €7,540 additional versus respectively. Sensitivity probabilities pregnancy, embryo transfer birth, key drivers costs. Scenario confirmed robustness outcomes. Conclusion: This suggests could result Further using real-world data, when available, recommended validate results present study.